A systematic review and meta-analysis of randomized controlled trials on the efficacy of Shensong Yangxin capsule for recurrence of atrial fibrillation after catheter ablation.
J EthnopharmacolMay 30, 2026 (epub)
Clinical ResearchCardiology
Tianshi Mao, Yuxuan Li, Jie Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of Shensong Yangxin (SSYX) capsules as adjunctive therapy for atrial fibrillation (AF) recurrence post-catheter ablation in 2199 patients across nine randomized controlled trials. The study found that SSYX combined with anti-arrhythmic drugs reduced early recurrence by 45% and late recurrence by 38% in persistent AF, with no significant difference in adverse events.
Key findings
- SSYX plus anti-arrhythmic drugs reduced early AF recurrence by 45% (RR 0.55, 95% CI: 0.42 to 0.71, P < 0.001).
- Late AF recurrence was reduced by 38% (RR 0.62, 95% CI: 0.47 to 0.81, P < 0.001) in persistent AF.
- No significant difference in adverse events was observed between SSYX and control groups.
Why it matters
The findings suggest that SSYX may serve as a beneficial adjunctive treatment for reducing AF recurrence after catheter ablation, potentially improving patient outcomes in this population.